Manipur HC: State Establishments Must Record Transgender Person’s New Name & Gender in Documents  ||  Delhi HC: Failure to Frame Counter Claim Despite Pleadings is Patently Illegal  ||  Mumbai Commission Holds Reliance Retail Liable for Defective AC Replacement Failure  ||  SC Orders ASI to Supervise Repair of Mehrauli’s Ancient Dargahs  ||  SC Reprimands Bihar IPS Officer for Affidavit Supporting Murder Convict  ||  SC Rejects Review Plea on WB SSC Jobs, Upholds Quashing of 25k Appointments  ||  SC Rejects Review Plea on WB SSC Jobs, Upholds Quashing of 25k Appointments  ||  Supreme Court Orders Haridwar Collector Inquiry into Maa Chandi Devi Trust  ||  SC Recommends Statutory Appeal Against DJ’s Compensation Orders  ||  SC Dismisses Petition Challenging 2024 Maharashtra Assembly Elections Over Bogus Voting    

CCI approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.- (Press Information Bureau) (16 Mar 2022)

MANU/PIBU/0878/2022

MRTP/ Competition Laws

The Competition Commission of India (CCI) approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.

The proposed combination pertains to the proposed acquisition of minority stake in Micro Life Sciences Private Limited (Micro Life/ Target) by South Elm Investments B.V. (SEI/ Acquirer).

SEI is an investment holding company incorporated under the laws of Netherlands. The shareholders of SEI are certain private equity funds managed by Warburg Pincus LLC.

Target is a company incorporated in India, which is primarily engaged in the following business activities in India along with subsidiaries: manufacture and sale of (a) medical devices in various categories such as stents, Percutaneous Transluminal Coronary Angioplasty catheters, heart valves, orthopedic implants, and endo-surgery products (such as sutures, staplers, meshes and intrauterine devices); (b) in-vitro diagnostics analyzers and reagents; and (c) over the counter (OTC) products like products COVID self-test kits and pregnancy test kits, in India. The Target (through its subsidiaries) is engaged in the B2C sale of certain specialized medical devices (such as surgical robots and ultrasonic energy devices) to hospitals and has research and development (R&D) facilities for in-vitro diagnostic, orthopedic, endo-surgery and cardiovascular solutions.

Tags : ACQUISITION   APPROVAL   MINORITY STAKE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved